Insys Therapeutics, a U.S. pharmaceutical company, gave the hefty sum of $500,000 to a group opposing the legalization of marijuana in Arizona in 2016.
Move forward to March 2017, the Arizona-based Insys Therapeutics received an approval from the U.S. federal agency, the Drug Enforcement Administration (EDA), to create Syndros, a synthetic marijuana drug.
Unlike marijuana, which is considered to be a prohibited schedule I drug, Syndros, a synthetic drug, was granted Schedule II classification, which allows it to become a federally regulated prescription drug.
Insys Therapeutics, which already manufactures opioid-based highly addictive drugs such as fentanyl, is having a change of hearts.
In late March, Insys Therapeutics filed an application, which can be seen online, asking EDA’s permission to be a “bulk manufacturer” of marijuana.
Specifically, the company is eyeing Tetrahydrocannabinol or THC, the psychoactive component found in marijuana, to make its synthetic medications.
The move shows how pharmaceutical companies are feeling the pressure to join the ever-growing marijuana trend, and at times their double standards.[share-btn]